id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2002-D-0022-0003,FDA,FDA-2002-D-0022,GUIDANCE,Supporting & Related Material,GDL-Guidance,2003-12-30T05:00:00Z,2003,12,,,2008-04-12T01:16:13Z,,0,0,0900006480488e12
FDA-2002-D-0022-0002,FDA,FDA-2002-D-0022,GUIDANCE,Supporting & Related Material,GDL-Guidance,2003-12-30T05:00:00Z,2003,12,,,2008-04-12T01:16:13Z,,0,0,0900006480488e0f
FDA-2002-D-0022-0004,FDA,FDA-2002-D-0022,FDA,Notice,NAD-Notice of Availability of Data,2003-12-30T05:00:00Z,2003,12,2003-12-19T05:00:00Z,2004-12-20T04:59:59Z,2008-04-12T01:16:13Z,,0,0,0900006480488e14
FDA-2002-D-0022-0001,FDA,FDA-2002-D-0022,Draft Guidance,Notice,NAD-Notice of Availability of Data,2003-01-27T05:00:00Z,2003,1,2003-01-27T05:00:00Z,2003-04-29T03:59:59Z,2008-04-12T01:16:13Z,,0,0,0900006480488dd3